Clinical trial
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
NCT00372073 · Cyclacel Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00372073 |
|---|---|
| Title | Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer |
| Official title | A Phase IIb Randomized Study of Oral Seliciclib in Patients With Previously Treated Non-Small Cell Lung Cancer |
| Lead sponsor | Cyclacel Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | seliciclib, placebo |
| Enrollment | 187 |
| Start date | Aug 9, 2006 |
| Primary completion | Mar 3, 2009 |
| Completion | Apr 7, 2009 |
| First posted | Sep 6, 2006 |
| Last update posted | Dec 22, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: